Citation:Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al 2004

Citation

Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004 May 1;22(9):1589-97 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15117980.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al 2004	What is the optimal systemic therapy for stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al 2004 2	What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al 2004 3	What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?|]] (compare critical appraisals)

Cited by

1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
2. What is the optimal systemic therapy for stage IV inoperable NSCLC?